The levels of circulating angiogenic and anti-angiogenic factors, namely vascular endothelial growth factor–A (VEGF-A) and soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), have been linked to the development of renal dysfunction due to the proliferation of microvasculature within the kidneys of type 2 diabetic (T2DM) patients. The study aims to scrutinize serum levels of VEGF and sVEGFR-1 in a sample of Iraqi diabetic nephropathy patients to support their reliability as markers for the prediction of nephropathy in type 2 diabetes mellitus patients as well as to assess the ACE inhibitor’s effect on the levels of these two markers. Method: The ninety participants of this case-control study were split into three groups: thirty-five patients with T2DM and an equal number of patients with DN and the third group involve twenty apparently healthy individuals as the control group. The two diabetic groups have been further divided into four groups according to the ACE inhibitors use. Laboratory measurements involve the glycemic indices, renal function test with serum VEGF-A and sVEGFR-1. Results: the median serum levels of VEGF-A show valuable discrepancies between the three groups (p-value<0.05) but for sVEGFR-1 it doesn’t show a notable difference between the DM and the DN groups only(p-value> 0.05).